Health economic assessment of Blenrep in the treatment of multiple myeloma

TLV

6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin). 

The assessment concerns the treatment of multiple myeloma in adult patients who have undergone at least four previous treatments and whose disease is refractory to at least one proteasome inhibitor, an immunomodulatory agent and an antiCD38 monoclonal antibody, with evidence of worsening of the disease at the last treatment.

Read TLV News [Swedish]

Michael Wonder

Posted by:

Michael Wonder